Skip to main content
. 2018 Sep 20;18(2):231–239. doi: 10.1007/s10689-018-0103-5

Table 3.

Genetics professionals’ experiences regarding providing genetic counselling for BRCA 1/2, CHEK2 and TP53-mutations during the initial counselling visit

n Yes Sometimes No
Do you discuss the options of BRCA1/2, CHEK2 and TP53-GT during the initial counselling visit?
 A. In case of referral for treatment-focused genetic counselling and testinga 49 73% (36) 27% (13)
 B. In case of a regular referral 54 58% (33) 33% (19) 4% (2)
Evaluation n (Totally) disagree Neutral (Totally) agree
In general I am able to provide sufficient information about clinical and genetic aspects of BRCA1/2, CHEK2 and TP53-mutations during a single counselling visit 54 9% (5) 15% (8) 76% (41)
In general I am able to pay enough attention to the decision making process for BRCA1/2, CHEK2 and TP53-GT during a single counselling visit 54 15% (8) 24% (13) 61% (33)
I have difficulties in providing accurate genetic counselling for BRCA 1/2, CHEK2 and TP53 during a single counselling visit 51 55% (28) 18% (9) 28% (14)

Sample size (n) is presented and varies per question due to missing data and because of the fact that some questions do not apply to all respondents. Percentages reflect the proportion of participants selecting the response category divided by the total number of respondents to the corresponding question or statement

LFS Li–Fraumeni syndrome, BC breast cancer, GT genetic testing

aReferral for treatment-focused genetic counselling and testing is indicated when decisions about primary breast cancer treatment could be impacted by genetic test results